Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05479812 · ClinicalTrials.gov registry record · Phase 1
Dose Escalation and Expansion Study of WTX-124 as Monotherapy and in Combination With Pembrolizumab (Pembro) in Patients With Selected Advanced or Metastatic Solid Tumors
A Phase 1 study of Advanced Solid Tumor and Metastatic Solid Tumor, sponsored by Werewolf Therapeutics.
- Active
- Registry status
- Phase 1
- Development phase
- 150
- Enrollment target
- 14
- Study locations
NCT05479812: Active Phase 1 study of Advanced Solid Tumor and Metastatic Solid Tumor, sponsored by Werewolf Therapeutics.
NCT05479812 is a Phase 1 study of Advanced Solid Tumor and Metastatic Solid Tumor that is active but no longer recruiting, run by Werewolf Therapeutics. The registered enrollment target is 150 participants, below the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (22% lower). The trial reports 14 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05479812, a Phase 1 study of Advanced Solid Tumor and Metastatic Solid Tumor, is active but no longer recruiting, sponsored by Werewolf Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 150 participants
- Enrollment target
- 14
- Study locations
Study Summary
A first-in-human, Phase I, open-label, multicenter study of WTX-124 administered as monotherapy and in combination with pembrolizumab to patients with advanced or metastatic solid tumors.
Conditions Studied
Interventions
- DRUG pembrolizumab
- DRUG WTX-124
Study Locations (14)
Texas
- Texas Oncology - Austin Midtown - Austin
- University of Texas Southwestern Medical Center - Dallas
- NEXT Oncology - Houston
- NEXT Oncology - San Antonio
New York
- Roswell Park Comprehensive Cancer Care - Buffalo
- Westchester Medical Center - Hawthorne
Arizona
- HonorHealth - Scottsdale
Florida
- Moffitt Cancer Center - Tampa
Georgia
- Emory Winship Cancer Institute - Atlanta
Illinois
- Northwestern University - Chicago
Indiana
- Indiana University Melvin and Bren Simon Comprehensive Cancer Center - Indianapolis
Minnesota
- Minnesota Oncology Hematology, P.A. - Maple Grove
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2022-05-20 |
| Est. Completion | 2026-07-31 |
| Phase | Phase 1 |
What the registry record for NCT05479812 still lists
NCT05479812 is an interventional study that assigns participants to a tested intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, below the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (22% lower).
The record links to 2 conditions, with Advanced Solid Tumor appearing as the primary indexed condition, and to 2 interventions - of which pembrolizumab is the first listed.
NCT05479812 lists 14 locations in 10 states (Texas, New York, Arizona).
Frequently Asked Questions
What is clinical trial NCT05479812 about?
NCT05479812 is a clinical study titled "Dose Escalation and Expansion Study of WTX-124 as Monotherapy and in Combination With Pembrolizumab (Pembro) in Patients With Selected Advanced or Metastatic Solid Tumors". A first-in-human, Phase I, open-label, multicenter study of WTX-124 administered as monotherapy and in combination with pembrolizumab to patients with advanced or metastatic solid tumors.
What is the current status of trial NCT05479812?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 150 participants. The study started on 2022-05-20. Estimated completion is 2026-07-31.
What conditions does trial NCT05479812 study?
This clinical trial studies the following conditions: Advanced Solid Tumor, Metastatic Solid Tumor.
What interventions are being tested in trial NCT05479812?
The interventions under investigation include: pembrolizumab (DRUG), WTX-124 (DRUG).
Who is sponsoring clinical trial NCT05479812?
This trial is sponsored by Werewolf Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05479812 being conducted?
This trial has 14 study locations across Arizona, Florida, Georgia, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05479812's enrollment target sits among peer trials
150 86th of 189 higher than 100 of 189 other Advanced Solid Tumor trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Advanced Solid Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
PM14 Administered Intravenously to Patients with Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study of EP0031 in Patients With Advanced RET-altered Malignancies
RECRUITING · Phase 1
-
Study of AVZO-021 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
- NCT01985919 · 150 participants
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
- NCT02016248 · 150 participants · NA
SBRT Boost for Unfavorable Prostate Cancer'
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI